Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29283292 | 0.81 | ALDH1A1 (0.38) | LMNAKDM4EALDH1A1NPC1TP53 | |
| SCHEMBL15694063 | 0.79 | DGKA (0.39) | LMNAALDH1A1NPC1TP53RAB9A | |
| SCHEMBL12028701 | 0.77 | LMNA (0.35) | LMNAALDH1A1NPC1TP53RAB9A | |
| SCHEMBL798062 | 0.77 | GAA (0.55) | LMNAALDH1A1MIFCYP1A2HSD17B10 | |
| SCHEMBL5710581 | 0.77 | — | — | |
| SCHEMBL4820356 | 0.77 | ALDH1A1 (0.39) | LMNAALDH1A1NPC1TP53RAB9A | |
| SCHEMBL11058319 | 0.75 | LMNA (0.34) | LMNAALDH1A1NPC1TP53RAB9A | |
| SCHEMBL697173 | 0.75 | LMNA (0.37) | LMNAALDH1A1NPC1TP53RAB9A | |
| SCHEMBL28737084 | 0.75 | — | — | |
| SCHEMBL21077427 | 0.74 | LMNA (0.35) | LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040048-B2 | Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug | SHIONOGI & CO., LTD. (JP) | 2021-06-22 | — | — | US | disclosed |
| US-20200261481-A1 | A MEDICAMENT FOR TREATING INFLUENZA CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-INFLUENZA DRUG | SHIONOGI & CO., LTD. (JP) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261481-A1 | A MEDICAMENT FOR TREATING INFLUENZA CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-INFLUENZA DRUG | RNASEH1, RNASEL, RNPEP | LMNA 1560/4885KDM4E 1312/4885ALDH1A1 1075/4885 |
| US-11040048-B2 | Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug | RNASEH1, RNPEP, RNASEL | LMNA 1825/4885KDM4E 1205/4885ALDH1A1 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.